IgPro10

ApprovedBiologic

IgPro10 is one of 74 biologic programs targeting Chronic Inflammatory Demyelinating Polyneuropathy. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Chronic Inflammatory Demyelinating PolyneuropathyActive, not recruiting

Thrombocytopenic PurpuraActive, not recruiting

Systemic SclerosisActive, not recruiting

Chronic Inflammatory Demyelinating PolyneuropathyPhase 3

Active, not recruiting

Thrombocytopenic PurpuraApproved

Active, not recruiting

Systemic SclerosisPhase 2

Active, not recruiting

Competition

Competitive Landscape

165 competitors in Systemic Sclerosis

#DrugCompanyPhaseTrials

Actemra

Roche

Phase 3

3 2

Fludara

Sanofi

Phase 3

3 3

Medrol

Pfizer

Phase 3

3 4

Opsumit

Johnson & Johnson

Phase 3

2 5

Rinvoq

AbbVie

Phase 3

1 6

Cysteine Hydrochloride

Novartis

Phase 3

1 7

Neupogen

EEastern Cooperative Oncology Group

Phase 3

1 8

UPLIZNA

HHorizon Therapeutics Ireland DAC

Phase 3

1 9

Ofev

Boehringer Ingelheim

Phase 3

1 10

Esbriet

LLegacy Health System

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2029

Post-ApprovalRecruiting

Pediatric

NCT03684018

Clinical

Trials by Indication[1]

Systemic Sclerosis2 trials

Efficacy and Safety of IgPro10 in Adults With Systemic Sclerosis (SSc)

Withdrawn· CSL Behring logo

CSL Behring·Phase 2·NCT04138485

Safety and Pharmacokinetics of IgPro20 and IgPro10 in Adults With Systemic Sclerosis (SSc)

Completed· CSL Behring logo

CSL Behring·Phase 2·NCT04137224·27 enrolled

Pediatric1 trial

Two Dose Levels of Privigen in Pediatric CIDP

Recruiting· CSL Behring logo

CSL Behring·Phase 4·NCT03684018·30 enrolled

Thrombocytopenic Purpura1 trial

A Safety Study of Intravenous Immunoglobulin in Patients With Chronic Immune Thrombocytopenic Purpura (ITP)

Completed· CSL Behring logo

CSL Behring·Phase 4·NCT01390649·57 enrolled

Chronic Inflammatory Demyelinating Polyneuropathy1 trial

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Treatment With Subcutaneous Immunoglobulin (IgPro20)

Completed· CSL Behring logo

CSL Behring·Phase 3·NCT01545076·208 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for IgPro10. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — IgPro10 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for IgPro10. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — CSL Behring company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Approved[1]
Company: CSL Behring

IgPro10

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2029

Trials by Indication[1]

Systemic Sclerosis2 trials

Pediatric1 trial

Thrombocytopenic Purpura1 trial

Chronic Inflammatory Demyelinating Polyneuropathy1 trial

References

Drug Info

Quick Facts

Related News